Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.

Trial Profile

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARGX 111 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors argenx
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 07 Jul 2017 Results published in an Argenx media release.
    • 07 Jul 2017 According to an Argenx media release, abstract covering the complete data set from this trial was presented at American Society of Clinical Oncology (ASCO) program at the 3rd Singapore Society of Oncology Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top